Edition:
United States

Acasti Pharma Inc (ACST.OQ)

ACST.OQ on NASDAQ Stock Exchange Capital Market

1.26USD
4:00pm EDT
Change (% chg)

$0.04 (+3.28%)
Prev Close
$1.22
Open
$1.23
Day's High
$1.26
Day's Low
$1.23
Volume
4,415
Avg. Vol
13,797
52-wk High
$3.09
52-wk Low
$1.11

Latest Key Developments (Source: Significant Developments)

Acasti Pharma Q2 loss per share $0.22
Tuesday, 11 Oct 2016 05:00pm EDT 

Acasti Pharma Inc : reports second quarter 2017 financial results . Qtrly loss per share $0.22 . if co does not raise additional funds, there exists uncertainty that casts substantial doubt about ability to continue as going concern .Management has reasonable expectation that corporation will be able to raise additional funds.  Full Article

Acasti posts qtrly loss per share of $0.29
Monday, 11 Jul 2016 05:30pm EDT 

Acasti Pharma Inc: Acasti announces first quarter results .Qtrly loss per share $0.29.  Full Article

Acasti Pharma says Jan D'Alvise named as CEO
Thursday, 12 May 2016 08:08am EDT 

Acasti Pharma Inc : Says Jan D'Alvise appointed as president and chief executive officer effective June 1, 2016 .Jan D'Alvise appointed president & CEO of Acasti Pharma.  Full Article

Acasti Pharma Inc says appointment of Roderick Carter, as Executive Chairman of the Board
Tuesday, 1 Mar 2016 08:00am EST 

Acasti Pharma Inc:Says appointment of Roderick Carter, as Executive Chairman of the Board.  Full Article

More From Around the Web

BRIEF-Acasti Pharma says has successfully completed two Phase 1, two Phase 2 clinical trials with Capre

* Acasti Pharma Inc - has successfully completed two Phase 1 and two Phase 2 clinical trials with Capre for treatment of hypertriglyceridemia